New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 15, 2026

Back to the front page

From X

@calvinblissett 1 click

Calvin Blissett on X

@MBoquard Thanks Michel. My take on $ANGI Q3: The quarter was better than the stock implies. • Revenue $242M, -9% YoY (improved from -11% in Q2), in line with consensus • Adj. EBITDA $42.2M vs ~$29M expected, 17.4% margin • Proprietary service requests flat at 3.8M, revenue per lead +10%, Large Pro revenue +20%+ • EPS missed ($0.03 vs $0.11), but that's non-cash accelerated depreciation from retiring the legacy platform The balance sheet isn't the problem I made it out to be: • $202.5M cash vs $398.7M of 3.875% notes due Aug 2028, not within a year • $175M revolver undrawn to 2030 • Bought back ~$100M of bonds below par YTD ($8.4M gain) • ~$196M net debt, roughly 1.5x EBITDA • At $5.99: ~$246M mkt cap, ~$440M EV, ~2.6x Q3 run-rate EBITDA, ~3.4x trailing The real problem is supply, not demand: • Avg monthly active pros 101K, -14% • Monthly pro churn 6.7% vs 5.9% a year ago • Leads -18%, network service requests -33% (partly deliberate cuts to low-quality traffic) • 9M FCF -$7M vs +$34M last year. Operating cash flow $38M vs $93M of adj. EBITDA, with $45M of capex during the platform migration • The 300-role cut ($50-60M run-rate savings) comes with $18-30M of restructuring charges through 1H27 What the AlphaSense expert calls say: • Former Angi VP (Oct 12): recent declines are "primarily due to a shrinking base of service providers, not a loss of homeowner demand or LLM-driven disruption." • Former Angi GM (Sep 22): believes the business "has already hit its lowest point" and sees "limited downside risk from current levels." Blames a poorly executed rebrand for the lost organic traffic. • Former Angi Director of Product (Sep 21): bearish. Sees conversational AI as "an existential threat" that could bypass marketplaces entirely. • Nextdoor marketing lead (Oct 14): Google AI Overviews pose "a significant threat to Angi's organic traffic," and Thumbtack is outspending Angi on brand. • Former Angi VP of Finance (Oct 12): skeptical the international margins can be replicated in the US; integration and cost work is "far from complete." How I see it: If pros stabilize, capex drops now that the migration is done, and they keep retiring notes below par, I get to roughly $60-80M of FCF in 2027 on a ~$246M market cap. That's my estimate, not guidance. If churn keeps rising and AI starts showing up in proprietary service requests, the 17% margin is just cost cuts on a shrinking business. What I'm watching: tomorrow's call (new CEO Mike Steib, ~45 days in) and the Nov 17 investor day for 2027 targets, pro count, capex and what they do with the cash. Not investment advice.
@ACapitalLP

A Capital on X

The 13% puke today is the market questioning whether $CVI is using peak-cycle earnings to justify a transformative acquisition (nearly doubling nameplate capacity). The $MPC assets may be attractive, but shareholders are absorbing dilution, additional debt, and the risk that refining margins normalize before the company can meaningfully delever… $CVI was always sub-scale, so there’s a legitimate strategic rationale here. The irony is that the best time to buy cyclical assets is usually when you can least afford to finance them…

Investor Letters

All letters

Q3 Earnings Updates

Q3 updates cover Crocs, Entravision and Fiserv beats, coal and oil weakness, and Xerox’s sharp decline, testing the underlying cases for…

CROX $7.5BEVC $874M
Hidden Rock Capital's Newsletter 3 clicks

TSOH Weekly Roundup (11/13/2026)

Tripadvisor’s CEO and CFO will depart after weak Q3 results, while Roblox’s CEO discusses AI and Berkshire repurchases $9.6 billion of…

TRIP $853M
TSOH Investment Research 3 clicks

IEH Corporation: Research Note

IEH Corporation posted Q2 revenue growth of 51% to $10.7 million and a record $56 million backlog, led by defense and medical demand.

IEHC $78M
Atrium Research - Equity Research 3 clicks

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

QURE $1.7B
Triple S Special Situations Investing 2 clicks

Big Short: Fidelity & Guaranty

F&G’s main insurer held $66.5 billion of assets against $1.38 billion of statutory capital, while private credit, reinsurance dependence…

FG $3B
Mispriced Assets 5 clicks

Peloton: Beyond The Bike

Peloton’s connected-fitness subscribers fell 9% year over year to 2.475 million, with another high-single-digit holiday decline forecast as…

PTON $2.5B
TSOH Investment Research 4 clicks
MONOY · long

Monotaro CO LTD

MonotaRO, traded as MONOY in the U.S. and 3064 in Japan, is a Japanese MRO distributor recommended as a long.

MONOY $7.3B
Value Investors Club 1 click

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 89 of 295

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.